Unknown

Dataset Information

0

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.


ABSTRACT: AIMS/HYPOTHESIS:Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up). METHODS:From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based on age, BMI, waist circumference, use of antihypertensive medication, smoking status and parental history of type 2 diabetes) and enrolled into a prospective cohort study (n = 2127) (cohort 1, prediabetes risk). We also recruited people from clinical registries with type 2 diabetes diagnosed 6-24 months previously (n = 789) into a second cohort study (cohort 2, diabetes). Follow-up examinations took place at ~18 months (both cohorts) and at ~48 months (cohort 1) or ~36 months (cohort 2) after baseline examinations. The cohorts were studied in parallel using matched protocols across seven clinical centres in northern Europe. RESULTS:Using ADA 2011 glycaemic categories, 33% (n = 693) of cohort 1 (prediabetes risk) had normal glucose regulation and 67% (n = 1419) had impaired glucose regulation. Seventy-six per cent of participants in cohort 1 was male. Cohort 1 participants had the following characteristics (mean ± SD) at baseline: age 62 (6.2) years; BMI 27.9 (4.0) kg/m2; fasting glucose 5.7 (0.6) mmol/l; 2 h glucose 5.9 (1.6) mmol/l. At the final follow-up examination the participants' clinical characteristics were as follows: fasting glucose 6.0 (0.6) mmol/l; 2 h OGTT glucose 6.5 (2.0) mmol/l. In cohort 2 (diabetes), 66% (n = 517) were treated by lifestyle modification and 34% (n = 272) were treated with metformin plus lifestyle modification at enrolment. Fifty-eight per cent of participants in cohort 2 was male. Cohort 2 participants had the following characteristics at baseline: age 62 (8.1) years; BMI 30.5 (5.0) kg/m2; fasting glucose 7.2 (1.4) mmol/l; 2 h glucose 8.6 (2.8) mmol/l. At the final follow-up examination, the participants' clinical characteristics were as follows: fasting glucose 7.9 (2.0) mmol/l; 2 h mixed-meal tolerance test glucose 9.9 (3.4) mmol/l. CONCLUSIONS/INTERPRETATION:The IMI DIRECT cohorts are intensely characterised, with a wide-variety of metabolically relevant measures assessed prospectively. We anticipate that the cohorts, made available through managed access, will provide a powerful resource for biomarker discovery, multivariate aetiological analyses and reclassification of patients for the prevention and treatment of type 2 diabetes.

SUBMITTER: Koivula RW 

PROVIDER: S-EPMC6677872 | biostudies-other | 2019 Sep

REPOSITORIES: biostudies-other

altmetric image

Publications

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium.

Koivula Robert W RW   Forgie Ian M IM   Kurbasic Azra A   Viñuela Ana A   Heggie Alison A   Giordano Giuseppe N GN   Hansen Tue H TH   Hudson Michelle M   Koopman Anitra D M ADM   Rutters Femke F   Siloaho Maritta M   Allin Kristine H KH   Brage Søren S   Brorsson Caroline A CA   Dawed Adem Y AY   De Masi Federico F   Groves Christopher J CJ   Kokkola Tarja T   Mahajan Anubha A   Perry Mandy H MH   Rauh Simone P SP   Ridderstråle Martin M   Teare Harriet J A HJA   Thomas E Louise EL   Tura Andrea A   Vestergaard Henrik H   White Tom T   Adamski Jerzy J   Bell Jimmy D JD   Beulens Joline W JW   Brunak Søren S   Dermitzakis Emmanouil T ET   Froguel Philippe P   Frost Gary G   Gupta Ramneek R   Hansen Torben T   Hattersley Andrew A   Jablonka Bernd B   Kaye Jane J   Laakso Markku M   McDonald Timothy J TJ   Pedersen Oluf O   Schwenk Jochen M JM   Pavo Imre I   Mari Andrea A   McCarthy Mark I MI   Ruetten Hartmut H   Walker Mark M   Pearson Ewan E   Franks Paul W PW  

Diabetologia 20190615 9


<h4>Aims/hypothesis</h4>Here, we describe the characteristics of the Innovative Medicines Initiative (IMI) Diabetes Research on Patient Stratification (DIRECT) epidemiological cohorts at baseline and follow-up examinations (18, 36 and 48 months of follow-up).<h4>Methods</h4>From a sampling frame of 24,682 adults of European ancestry enrolled in population-based cohorts across Europe, participants at varying risk of glycaemic deterioration were identified using a risk prediction algorithm (based  ...[more]

Similar Datasets

| S-EPMC4018481 | biostudies-literature
| S-EPMC10156700 | biostudies-literature
| S-EPMC6482967 | biostudies-literature
| S-EPMC7078183 | biostudies-literature
| S-EPMC6448965 | biostudies-literature
| S-EPMC8188482 | biostudies-literature
| S-EPMC6596252 | biostudies-literature
| S-EPMC4976867 | biostudies-literature
| S-EPMC3899557 | biostudies-other
| S-EPMC9282674 | biostudies-literature